HK1145419A1 - Topical use of r()-n-propargyl-1-aminoindan to treat or prevent hearing loss r()-n--1- - Google Patents

Topical use of r()-n-propargyl-1-aminoindan to treat or prevent hearing loss r()-n--1-

Info

Publication number
HK1145419A1
HK1145419A1 HK10111972.7A HK10111972A HK1145419A1 HK 1145419 A1 HK1145419 A1 HK 1145419A1 HK 10111972 A HK10111972 A HK 10111972A HK 1145419 A1 HK1145419 A1 HK 1145419A1
Authority
HK
Hong Kong
Prior art keywords
aminoindan
propargyl
treat
hearing loss
topical use
Prior art date
Application number
HK10111972.7A
Other languages
English (en)
Chinese (zh)
Inventor
Balazs Lendvai
Vizi Szilveszter
Zelles Tibor
Halmos Gyorgy
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1145419A1 publication Critical patent/HK1145419A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK10111972.7A 2007-09-17 2010-12-22 Topical use of r()-n-propargyl-1-aminoindan to treat or prevent hearing loss r()-n--1- HK1145419A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99422207P 2007-09-17 2007-09-17
PCT/US2008/010836 WO2009038732A1 (en) 2007-09-17 2008-09-17 Use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss

Publications (1)

Publication Number Publication Date
HK1145419A1 true HK1145419A1 (en) 2011-04-21

Family

ID=40455263

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111972.7A HK1145419A1 (en) 2007-09-17 2010-12-22 Topical use of r()-n-propargyl-1-aminoindan to treat or prevent hearing loss r()-n--1-

Country Status (10)

Country Link
US (1) US8188149B2 (xx)
EP (1) EP2203050B1 (xx)
JP (1) JP5599711B2 (xx)
AU (1) AU2008301864B2 (xx)
CA (1) CA2699960C (xx)
ES (1) ES2445065T3 (xx)
HK (1) HK1145419A1 (xx)
IL (1) IL204339A (xx)
PT (1) PT2203050E (xx)
WO (1) WO2009038732A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
NZ571591A (en) * 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
EP3488837A1 (en) * 2009-07-15 2019-05-29 NewSouth Innovations Pty Limited Electroporation apparatus for providing agents to the cochlea
EA023786B1 (ru) 2010-04-30 2016-07-29 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальные композиции на основе пропиниламиноиндана
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
WO2015168149A2 (en) * 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
KR20170025992A (ko) * 2015-08-31 2017-03-08 삼성전자주식회사 복합 양극, 양극-막 조립체, 이를 포함하는 전기 화학 전지 및 양극-막 조립체 제조방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
EP1052983A2 (en) 1998-01-27 2000-11-22 Thomas N. Thomas Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
DE19924802B4 (de) * 1999-05-29 2008-02-28 Basf Ag Verfahren zur Herstellung von schalldämpfenden und energieabsorbierenden Polyurethanschäumen
AU2003290838A1 (en) 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
WO2006058250A2 (en) * 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
ZA200704917B (en) 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US20070021352A1 (en) 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
AU2006316585B2 (en) 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
WO2008100966A1 (en) * 2007-02-12 2008-08-21 The Research Foundation Of State University Of New York Gdnf-derived peptides
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
AU2008339607B2 (en) 2007-12-24 2012-08-02 Cipla Limited Process for the synthesis of propargylated aminoindan derivatives
CN101909438A (zh) 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
EP2271612B1 (en) 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
ES2389353T3 (es) 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
CA2727021A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
CN101606923B (zh) 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
EA201170181A1 (ru) 2008-07-11 2011-08-30 Синтон Бв Полиморфные формы разагилина гидрохлорида
WO2010007181A2 (en) 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
US20100029987A1 (en) 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
EP2321258A1 (en) 2008-07-30 2011-05-18 Generics [UK] Limited Polymorphic form of rasagiline mesylate
EP2181980A1 (en) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
US20110015274A1 (en) 2009-07-20 2011-01-20 Ester Masllorens Llinas Form of an aminoindan mesylate derivative
AU2010274589A1 (en) 2009-07-23 2012-02-16 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof

Also Published As

Publication number Publication date
AU2008301864B2 (en) 2013-06-06
WO2009038732A1 (en) 2009-03-26
AU2008301864A1 (en) 2009-03-26
EP2203050A1 (en) 2010-07-07
CA2699960C (en) 2017-02-28
ES2445065T3 (es) 2014-02-28
CA2699960A1 (en) 2009-03-26
IL204339A (en) 2016-03-31
US20090076160A1 (en) 2009-03-19
JP2010539235A (ja) 2010-12-16
JP5599711B2 (ja) 2014-10-01
EP2203050B1 (en) 2013-11-06
US8188149B2 (en) 2012-05-29
EP2203050A4 (en) 2011-01-12
PT2203050E (pt) 2014-02-11

Similar Documents

Publication Publication Date Title
HK1145419A1 (en) Topical use of r()-n-propargyl-1-aminoindan to treat or prevent hearing loss r()-n--1-
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
ZA201000436B (en) Novel esterases and their use
IL206145A0 (en) Wearable towel
GB0715556D0 (en) Improvements relating to skin dressings
GB0716605D0 (en) Skin antiseptics
HK1184053A1 (zh) 用於皮膚增强的蘆薈製劑
EP2185173A4 (en) USE OF PHOSPHATASES FOR TREATING NEUROBLASTOMES AND MEDULLOBLASTOMES
ZA200906187B (en) Reducing side effects of tramadol
PL2209458T3 (pl) Kompozycje do traktowania skóry
EP2215035A4 (en) BISULFIT TREATMENT OF RNA
EP2249765A4 (en) DAPSONE TO TREAT THE ROSACEA
ZA201000225B (en) Treatment of depression
EG26571A (en) Its composition consists of a treatment component and a carrier for water treatment
GB2451060B (en) Dual coatings applied to medical devices
GB0724813D0 (en) Improvements relating to water treatment
GB0723100D0 (en) Treatment of HFnEF
GB2446447B (en) Tissue tensiometer
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
GB0622920D0 (en) Topical treatment
AU2007905373A0 (en) Topical use of thiolatocobalamins
GB0705204D0 (en) Uses of (S)-clenbuterol
GB2440640B (en) Structure of inline skates
AU2007902050A0 (en) Treatment of Nickel-Containing Solutions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170917